0000000001190558

AUTHOR

M Popescu

showing 2 related works from this author

Fluid challenges in intensive care: the FENICE study: a global inception cohort study

2015

Background: Fluid challenges (FCs) are one of the most commonly used therapies in critically ill patients and represent the cornerstone of hemodynamic management in intensive care units. There are clear benefits and harms from fluid therapy. Limited data on the indication, type, amount and rate of an FC in critically ill patients exist in the literature. The primary aim was to evaluate how physicians conduct FCs in terms of type, volume, and rate of given fluid; the secondary aim was to evaluate variables used to trigger an FC and to compare the proportion of patients receiving further fluid administration based on the response to the FC. Methods: This was an observational study conducted i…

MaleSoins intensifs réanimationmedicine.medical_treatmentCohort Studies; Female; Humans; Male; Middle Aged; Practice Patterns Physicians'; Critical Care; Fluid Therapy; Critical Care and Intensive Care MedicinePractice PatternsESICM Trial GroupCritical Care and Intensive Care MedicineRESPONSIVENESSCohort StudiesSeven-Day Profile PublicationMedicine and Health SciencesPractice Patterns Physicians'FENICE InvestigatorsCIRCULATORY SHOCKintensive careddc:617RENAL REPLACEMENT THERAPYMiddle Aged3. Good healthOF-THE-LITERATURESHOCKFemalelipids (amino acids peptides and proteins)Erratumintensive care fluid therapyfluidsLife Sciences & BiomedicineCRITICALLY-ILL PATIENTSHumanCohort studymedicine.medical_specialtyCritical CareHYDROXYETHYL STARCH 130/0.4MEDLINE1117 Public Health and Health ServicesNOfluid therapyCritical Care MedicineCIRCULATORYGeneral & Internal MedicineIntensive careAnesthesiologyPATIENTSmedicinecohort studyHumansRenal replacement therapyIntensive care medicineintensive care; fluids; cohort studyPhysicians'Science & TechnologyCRITICALLY-ILLbusiness.industrySeptic shockSEPTIC SHOCK1103 Clinical Sciences3126 Surgery anesthesiology intensive care radiologymedicine.diseaseEmergency & Critical Care MedicineARTERIAL-PRESSURESEVERE SEPSISClinical trialFluid TherapyObservational studyCohort Studiebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyTASK-FORCE
researchProduct

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

2017

Item does not contain fulltext BACKGROUND: Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent re…

MaleSTATIN THERAPYAnticholesteremic Agents/adverse effectsAntibodieVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Injections Subcutaneous/adverse effects030204 cardiovascular system & hematologyBococizumablaw.inventionPCSK90302 clinical medicineRandomized controlled triallawRisk FactorsGENETIC-VARIANTSCardiovascular DiseaseMonoclonalAnticholesteremic Agent030212 general & internal medicineMyocardial infarctionTreatment FailureHumanizedProprotein Convertase 9/antagonists & inhibitorsMedicine(all)Antibodies; Antibodies Monoclonal Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol LDL; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Injections Subcutaneous; Lipids; Male; Middle Aged; Proprotein Convertase 9; Risk Factors; Treatment Failure; Medicine (all)Anticholesteremic AgentsMedicine (all)PCSK9 InhibitorsAntibodies; antibodies monoclonal humanized; anticholesteremic agents; cardiovascular diseases; cholesterol LDL; double-blind method; female; follow-up studies; humans; hypercholesterolemia; injections subcutaneous; lipids; male; middle aged; proprotein convertase 9; risk factors; treatment failure; medicine (all)Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16]General MedicineLipidMiddle AgedLipids3. Good healthLDL/bloodMulticenter StudyCholesterolTRIALSCholesterol LDL/bloodCardiovascular DiseasesAntibodies Monoclonal Humanized/adverse effectsanticholesteremic agentsRandomized Controlled Trialsubcutaneouslipids (amino acids peptides and proteins)FemaleProprotein Convertase 9Cardiovascular Diseases/prevention & controlREDUCING LIPIDSHumanmedicine.medical_specialtyanimal structuresInjections SubcutaneousHypercholesterolemiaHypercholesterolemia/drug therapyPlaceboAntibodies Monoclonal HumanizedInjections SubcutaneouAntibodiesLDLInjectionsFollow-Up StudielipidsEVENTS03 medical and health sciencesantibodies monoclonal humanizedDouble-Blind MethodInternal medicinemedicineJournal ArticleHumansComparative StudyMETAANALYSISAlirocumabbusiness.industryUnstable anginaLipids/bloodPCSK9Risk FactorfungiAntibodies/bloodCholesterol LDLta3121medicine.diseaseSurgerycardiovascular diseasesEvolocumabREDUCTIONHumanized/adverse effectsSubcutaneous/adverse effectsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct